Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Docetaxel × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 28 Thoracic 28 Breast 20 Genitourinary 19 Gastrointestinal 13 Head & Neck 7 Dermatologic 7 Gynecologic 3 Sarcoma 2 Other solid neoplasm 2 Lymphoid 2 Plasma cell 1 Other hematologic neoplasm 1 Endocrine 1 CNS 1

Conditions

Thyroid Carcinoma, Anaplastic 2 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Prostatic Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Esthesioneuroblastoma, Olfactory 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Neuroendocrine 1 Carcinoma, Medullary 1 Breast Neoplasms, Male 1 Breast Neoplasms 1 Adrenocortical Carcinoma 1 Adenocarcinoma, Follicular 1

Interventions

Everolimus 6 Sunitinib 4 Octreotide 4 Leucovorin 4 dabrafenib 3 Fluorouracil 3 trametinib 2 selpercatinib 2 lutetium Lu 177 dotatate 2 PM 01183 2 Oxaliplatin 2 Irinotecan 2 Fulvestrant 2 Doxorubicin 2 Cisplatin 2 3-Iodobenzylguanidine 2 tipifarnib 1 telotristat ethyl 1 somapacitan 1 ribociclib 1 repotrectinib 1 pralsetinib 1 pentetreotide 1 pasireotide 1 motesanib diphosphate 1 irinotecan sucrosofate 1 epothilone B 1 entinostat 1 dostarlimab 1 dactolisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03837977 2024-12-30

NET02

The Christie NHS Foundation Trust

Phase 2 Completed

Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡